2647949-48-0
2647949-48-0
Chemical Structure
Ontunisertib
Synonym(s): AGMB-129
- CAS No.: 2647949-48-0
- Formula:C27H21F2N5O
- Molecular Weight:469.49
InChIKey: QGXRIRYULXOGDQ-UHFFFAOYSA-N
SMILES: O=C(CN1N=C(C(C2=C3C=CC=CC3=NC=C2)=C1)C4=CC=CC(C)=N4)NCC5=C(F)C=CC=C5F
Biological Activity: Ontunisertib (AGMB-129) is an orally active and selective gastrointestinal-restricted ALK5 (TGFβR1) inhibitor. Ontunisertib blocks signalling of the pro-fibrotic TGFβ pathway. Ontunisertib can be used for the research of fibrostenotic Crohn’s disease[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ontunisertib | 99.95% | Ontunisertib (AGMB-129) is an orally active and selective gastrointestinal-restricted ALK5 (TGFβR1) inhibitor. Ontunisertib blocks signalling of the pro-fibrotic TGFβ pathway. Ontunisertib can be used for the research of fibrostenotic Crohn’s disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. F Rieder, et al. OP20 Results from the STENOVA trial: A Phase 2a, randomized, placebo-controlled, double-blind study to assess the safety, pharmacokinetics (PK), and pharmacodynamics of ontunisertib (AGMB-129) in patients with Fibrostenotic Crohn’s Disease (FSCD). Journal of Crohn's and Colitis, Volume 20, Issue Supplement_1, January 2026, jjaf231.020.
- [2]. A. Sáez-Borderías, et al. P0334 AGMB-129, an investigational ALK5 inhibitor for the treatment of Fibrostenosing Crohn’s Disease (FSCD), shows gastrointestinal (GI) restricted pharmacokinetics (PK) and a favorable safety profile in healthy subjects. 275836923.
